Sponsor Check › Group linked by Ronald Seidel III › Issuer
Corporation · organized in DELAWARE · formed more than five years before filing · BOSTON, MA · SEC CIK 1645460 · formerly Imagen Biopharma, Inc.
Part of sponsor group: Group linked by Ronald Seidel III (2 issuers, 9 filings) · grouped because: shared people, same person name on both filings · confidence 100% · Not the same sponsor? Request a correction
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Jul 22, 2026 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known only from an approved profile claim or its Form ADV) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.
4 of 6 offerings report sales commissions totalling $5,920,745; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jul 22, 2026 D File 021-591745 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 14, 2026 D File 021-584091 | $1,800,000 | $0 | $0 | Newbridge Securities Corporation BrokerCheck CRD 104065 ↗ |
| EDGAR ↗ | Nov 21, 2022 D File 021-465492 | $1,800,000 | $0 | $0 | Piper Sandler & Co. BrokerCheck CRD 665 ↗ Public Ventures, LLC BrokerCheck CRD 42677 ↗ |
| EDGAR ↗ | Dec 30, 2016 D/A File 021-276931 | $1,320,745 | $0 | $0 | MDB Capital Group, LLC BrokerCheck CRD 42677 ↗ |
| EDGAR ↗ | Jun 19, 2015 D File 021-242130 | $1,000,000 (est.) | $0 | $0 | MDB Capital Group, LLC BrokerCheck CRD 42677 ↗ |
| EDGAR ↗ | Jun 19, 2015 D File 021-242131 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
0 recorded documents and 0 ownership records matched to Cue Biopharma, Inc. in the sources searched.
Not found in sources searched (no on-demand check has run yet): NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c); NYC PLUTO ownership via NYC Open Data (64uk-42ks); Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp); Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files). Records in other counties, and recorder indexes we do not yet cover, were not searched.
Property records coverage: New York City (ACRIS recorded documents and ownership, refreshed monthly); Hillsborough County FL (recorded documents from Oct 14, 2026 forward; ownership from FL DOR roll 2026); Cook County IL, Harris County TX, Dallas County TX (assessor ownership and deed/sale records only); Miami-Dade County FL (ownership from FL DOR roll only; Clerk recorded documents not yet searched). Recorder indexes for TX, AZ, IL and WA counties, mortgages and liens outside NYC and FL, lis pendens and foreclosure notices everywhere, Miami-Dade County FL recorded documents, Maricopa County AZ, King County WA, Salt Lake County UT, and all other counties are not yet searched. Last refresh: Oct 23, 2026, 11:02 PM ET. Sources searched: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET · Florida DOR NAL roll (Hillsborough 39) roll year 2026 — loaded Oct 23, 2026, 8:54 PM ET · Florida DOR NAL roll (Dade 23) roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET · Harris County Appraisal District real_acct.txt roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET · Dallas Central Appraisal District ACCOUNT_INFO.CSV roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET. Not yet searched for this issuer (queued): NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Counterparties that are not business entities are shown as "an individual (name withheld)"; residential addresses are never shown. Items still in human review are not shown.
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|---|---|---|---|---|---|
| 021-591745 | Jul 22, 2026 EDGAR ↗ | Jul 22, 2026 D EDGAR ↗ | 0 | $49,999,927 | $49,999,927 | Biotechnology |
| 021-584091 | May 14, 2026 EDGAR ↗ | May 14, 2026 D EDGAR ↗ | 0 | $29,999,992 | $29,999,992 | Biotechnology |
| 021-465492 | Nov 21, 2022 EDGAR ↗ | Nov 21, 2022 D EDGAR ↗ | 0 | $29,999,993 | $29,999,993 | Biotechnology |
| 021-276931 | Dec 22, 2016 EDGAR ↗ | Dec 30, 2016 D/A EDGAR ↗ | 1 latest Dec 30, 2016 | $16,414,900 | $16,414,900 | Biotechnology |
| 021-242131 | Jun 19, 2015 EDGAR ↗ | Jun 19, 2015 D EDGAR ↗ | 0 | $1,000,000 | $0 | Biotechnology |
| 021-242130 | Jun 19, 2015 EDGAR ↗ | Jun 19, 2015 D EDGAR ↗ | 0 | $10,000,000 | $10,000,000 | Biotechnology |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
| Filing | Form D filed Jul 22, 2026 SEC file no. 021-591745 · accession 0001645460-26-000004 |
|---|---|
| Raise progress | $49,999,927 sold of $49,999,927 offered (100%) · $0 remaining · first sale Jul 13, 2026 |
| Filing timing | Date of first sale: Jul 13, 2026 · Form D filed: Jul 22, 2026 (9 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 103 days (0.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 4 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Sumita Ray, JD, Chief Legal & Compliance Officer (Jul 22, 2026) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $49,999,927. Typical range: $2,000,000–$19,999,994. Investors: 4. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed May 14, 2026 SEC file no. 021-584091 · accession 0001645460-26-000003 |
|---|---|
| Raise progress | $29,999,992 sold of $29,999,992 offered (100%) · $0 remaining · first sale May 4, 2026 |
| Filing timing | Date of first sale: May 4, 2026 · Form D filed: May 14, 2026 (10 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 173 days (0.5 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 118 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Pre-funded warrants to purchase shares of Common Stock |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | Newbridge Securities Corporation — FINRA BrokerCheck CRD 104065 ↗ Solicits in: All States |
| Money to insiders | Sales commissions: $1,800,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Sumita Ray, JD, Chief Legal & Compliance Officer (May 14, 2026) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $29,999,992. Typical range: $2,000,000–$19,999,994. Investors: 118. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Nov 21, 2022 SEC file no. 021-465492 · accession 0001645460-22-000005 |
|---|---|
| Raise progress | $29,999,993 sold of $29,999,993 offered (100%) · $0 remaining · first sale Nov 16, 2022 |
| Filing timing | Date of first sale: Nov 16, 2022 · Form D filed: Nov 21, 2022 (5 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,438 days (3.9 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 64 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | Piper Sandler & Co. — FINRA BrokerCheck CRD 665 ↗ Solicits in: All States Public Ventures, LLC — FINRA BrokerCheck CRD 42677 ↗ Solicits in: All States |
| Money to insiders | Sales commissions: $1,800,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Kerri-Ann Millar, Chief Financial Officer (Nov 21, 2022) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $29,999,993. Typical range: $2,000,000–$19,999,994. Investors: 64. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D/A (amendment) filed Dec 30, 2016 · amends 0001645460-16-000004 ↗ SEC file no. 021-276931 · accession 0001645460-16-000005 · filing 2 of 2 in this offering |
|---|---|
| Raise progress | $16,414,900 sold of $16,414,900 offered (100%) · $0 remaining · first sale Dec 22, 2016 |
| Filing timing | Date of first sale: Dec 22, 2016 · Original Form D filed: Dec 22, 2016 (0 days after first sale) · This amendment (Form D/A) filed: Dec 30, 2016 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
| Time since first sale | 3,593 days (9.8 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Dec 30, 2016. Most recent amendment for this offering in our index: this filing, Dec 30, 2016. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 133 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | MDB Capital Group, LLC — FINRA BrokerCheck CRD 42677 ↗ Solicits in: AR, AZ, CA, CO, CT, FL, IL, IN, MA, MD, MI, MN, MO, NJ, NV, NY, SC, TN, TX, VA, WA, WI |
| Money to insiders | Sales commissions: $1,320,745 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Daniel Passeri, Chief Executive Officer (Dec 29, 2016) |
| Changes vs previous filing |
Compared with the D filed Dec 22, 2016 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $16,414,900. Typical range: $2,000,000–$19,999,994. Investors: 133. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Dec 22, 2016 SEC file no. 021-276931 · accession 0001645460-16-000004 · filing 1 of 2 in this offering |
|---|---|
| Raise progress | $20,000,000 sold of $20,000,000 offered (100%) · $0 remaining · first sale Dec 22, 2016 |
| Filing timing | Date of first sale: Dec 22, 2016 · Form D filed: Dec 22, 2016 (0 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 3,593 days (9.8 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Dec 30, 2016 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 133 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | MDB Capital Group, LLC — FINRA BrokerCheck CRD 42677 ↗ Solicits in: AR, AZ, CA, CO, CT, FL, IL, IN, MA, MD, MI, MN, MO, NJ, NV, NY, SC, TN, TX, VA, WA, WI |
| Money to insiders | Sales commissions: $1,500,000 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Daniel Passeri, Chief Executive Officer (Dec 22, 2016) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $20,000,000. Typical range: $2,000,000–$19,999,994. Investors: 133. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Jun 19, 2015 SEC file no. 021-242131 · accession 0001140361-15-024837 |
|---|---|
| Raise progress | $0 sold of $1,000,000 offered (0%) · $1,000,000 remaining · first sale Jun 15, 2015 Issuer's note: Reflects proceeds upon exercise of warrant. |
| Filing timing | Date of first sale: Jun 15, 2015 · Form D filed: Jun 19, 2015 (4 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 4,149 days (11.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Cameron Gray, President and CEO (Jun 17, 2015) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $1,000,000. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Jun 19, 2015 SEC file no. 021-242130 · accession 0001140361-15-024836 |
|---|---|
| Raise progress | $10,000,000 sold of $10,000,000 offered (100%) · $0 remaining · first sale Jun 15, 2015 |
| Filing timing | Date of first sale: Jun 15, 2015 · Form D filed: Jun 19, 2015 (4 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 4,149 days (11.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 121 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | MDB Capital Group, LLC — FINRA BrokerCheck CRD 42677 ↗ Solicits in: AR, AZ, CA, CO, CT, DE, FL, IL, IN, KY, MD, NJ, NY, PA, SC, TN, TX, VA, WA, WI |
| Money to insiders | Sales commissions: $1,000,000 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 Issuer's note: Placement Agent, MDB Capital Group, LLC, received cash fee equal to 10% of shares sold and warrant to purchase 10% of shares sold (370,370). |
| Signed by | Cameron Gray, President and CEO (Jun 17, 2015) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $10,000,000. Typical range: $2,000,000–$19,999,994. Investors: 121. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|---|---|---|
| Dec 30, 2016 EDGAR ↗ | 021-276931 | Dec 22, 2016 D | total sold: $20,000,000 (Dec 22, 2016) → $16,414,900 (Dec 30, 2016) · total offering: $20,000,000 (Dec 22, 2016) → $16,414,900 (Dec 30, 2016) · sales commissions: $1,500,000 (Dec 22, 2016) → $1,320,745 (Dec 30, 2016) |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. History: 2 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Jul 22, 2026. Industry as reported, by offering: All 6 offerings reported: Biotechnology (2015–2026).
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|---|---|---|---|
| Daniel Camardo | Director | MA | Jul 22, 2026 on 1 of 7 filings listed on the latest filing | — |
| Dominic Borie | Executive Officer | MA | Jul 22, 2026 on 1 of 7 filings listed on the latest filing | — |
| Michael Meluzio | Executive Officer | MA | Jul 22, 2026 on 1 of 7 filings listed on the latest filing | — |
| Pamela D. Garzone also filed as Pamela Garzone | Director | MA | May 14, 2026 → Jul 22, 2026 on 2 of 7 filings listed on the latest filing | — |
| Pasha Sarraf | Director | MA | May 14, 2026 → Jul 22, 2026 on 2 of 7 filings listed on the latest filing | — |
| Shao-Lee Lin | Executive Officer, Director | MA | May 14, 2026 → Jul 22, 2026 on 2 of 7 filings listed on the latest filing | — |
| Sumita Ray | Executive Officer | MA | Jul 22, 2026 on 1 of 7 filings listed on the latest filing | — |
| Viola Meehan | Director | MA | Jul 22, 2026 on 1 of 7 filings listed on the latest filing | — |
| Colin G. Sandercock also filed as Colin Sandercock | Executive Officer | MA | Nov 21, 2022 → May 14, 2026 on 2 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Daniel Baker | Executive Officer | MA | May 14, 2026 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | 1 other issuer |
| Frank G. Morich also filed as Frank Morich | Director | MA | Nov 21, 2022 → May 14, 2026 on 2 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Jill M. Broadfoot | Director | MA | May 14, 2026 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| PETER KIENER also filed as Peter A. Kiener; Peter Kiener | Director | MA | Dec 22, 2016 → May 14, 2026 on 4 of 7 filings not listed on the latest filing (Jul 22, 2026) | 1 other issuer |
| Patrick Verheyen | Director | MA | May 14, 2026 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Aaron G. Fletcher | Director | MA | Nov 21, 2022 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Anish R. Suri | Executive Officer | MA | Nov 21, 2022 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Daniel R. Passeri also filed as DANIEL PASSERI | Executive Officer, Director Issuer's note: Chief Executive Officer | MA | Dec 22, 2016 → Nov 21, 2022 on 3 of 7 filings not listed on the latest filing (Jul 22, 2026) | 1 other issuer |
| Frederick G. Driscoll | Director | MA | Nov 21, 2022 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Ken R. Pienta | Executive Officer | MA | Nov 21, 2022 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Kerri-Ann R. Millar | Executive Officer | MA | Nov 21, 2022 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Patricia R. Nasshorn | Executive Officer | MA | Nov 21, 2022 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Tamar G. Howson | Director | MA | Nov 21, 2022 on 1 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Amy Wang also filed as AMY WANG | Executive Officer, Director Issuer's note: Secretary | MA | Jun 19, 2015 → Dec 30, 2016 on 4 of 7 filings not listed on the latest filing (Jul 22, 2026) | 4 other issuers |
| Anthony DiGiandomenico also filed as ANTHONY DIGIANDOMENICO | Director | MA | Jun 19, 2015 → Dec 30, 2016 on 4 of 7 filings not listed on the latest filing (Jul 22, 2026) | 3 other issuers |
| BARRY SIMON | Director | MA | Dec 22, 2016 → Dec 30, 2016 on 2 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Cameron Gray also filed as CAMERON GRAY | Executive Officer, Director Issuer's note: Chief Executive Officer and President | MA | Jun 19, 2015 → Dec 30, 2016 on 4 of 7 filings not listed on the latest filing (Jul 22, 2026) | 3 other issuers |
| Christopher Marlett also filed as CHRISTOPHER MARLETT | Director | MA | Jun 19, 2015 → Dec 30, 2016 on 4 of 7 filings not listed on the latest filing (Jul 22, 2026) | 4 other issuers |
| Gary Schuman also filed as GARY SCHUMAN | Executive Officer, Director Issuer's note: Chief Financial Officer | MA | Jun 19, 2015 → Dec 30, 2016 on 4 of 7 filings not listed on the latest filing (Jul 22, 2026) | 1 other issuer |
| Rodolfo Chaparro also filed as RODOLFO CHAPARRO | Executive Officer Issuer's note: Vice President, Head of Immunology | MA | Jun 19, 2015 → Dec 30, 2016 on 4 of 7 filings not listed on the latest filing (Jul 22, 2026) | 1 other issuer |
| Ronald Seidel III also filed as RONALD SEIDEL III | Executive Officer Issuer's note: Executive Vice President, Head of Research and Development | MA | Jun 19, 2015 → Dec 30, 2016 on 4 of 7 filings not listed on the latest filing (Jul 22, 2026) | 1 other issuer |
| STEVEN MCKNIGHT | Director | MA | Dec 22, 2016 → Dec 30, 2016 on 2 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
| Steven Almo | Executive Officer Issuer's note: Chairman of Scientific Advisory Board | CA | Jun 19, 2015 on 2 of 7 filings not listed on the latest filing (Jul 22, 2026) | — |
Executive officers, directors and promoters as self-reported by the issuer; spelling variants of one person are merged. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Other issuers listing the same people:
Shared address: this business address appears on filings for 3 other issuers. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Not yet searched. Sources to be searched: SEC Investment Adviser Information Reports — Form ADV data for SEC-registered advisers and exempt reporting advisers (file dated 2026-10-02); SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected.
Sources to be searched: sponsor website, Internet Archive, press index (GDELT), Form ADV. A sponsor's website is known only from an approved profile claim or the issuer's own Form ADV; we never look it up elsewhere and never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for MA yet).
Export this report as PDF (all source links + data timestamp; members · included free during the launch period)
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.
The complete public-record profile for Cue Biopharma, Inc., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.